This distinguishes it from native GLP-1 which has a half-life of only 12 minutes
It may be considered: During periods of high stress or fatigue During recovery from illness or surgery When clinical history suggests deficiency risk As part of a broader, supportive infusion plan All decisions are guided by clinical assessment , not symptom trends
It has also raised new questions about affordability
As of 2026, it is in Phase 3 trials and has not received FDA approval for any indication
However, a shortage doesn't negate the need for a legal, safe, and approved source drug, which in this case, ironically, are the ones in short supply
The prior authorization guidelines are detailed in this Medicaid bulletin